Within patients undergoing RadioFrequency Ablation for locally advanced pancreatic cancer, SMAD4 analysis could segregate a subgroup of subjects with improved survival, who likely benefited from tumor ablation
Testing for genetic mutations continues to reveal information to cancer patients. The study linked below talks about SMAD4 analysis in locally advanced pancreatic cancer patients as being a possible positive prognostic indicator.
The bottom line is that the bad news is that you have pancreatic cancer. The good news is that if you test for SMAD4 you may respond well to radio frequency ablation.
Conventional oncology is limited in what they can do for pancreatic cancer patients. Please consider integrative therapies such as curcumin which has been shown to enhance the efficacy of a standard chemotherapy regimen called cisplatin.
I supplement and recommend Life Extension SuperBio Curcumin because of its enhanced bioavailability.
I am both a cancer survivor and cancer coach. Please scroll down the page, post a question or comment and I will reply to you ASAP.
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients
“Purpose– SMAD4 mutational status correlates with pancreatic ductal adenocarcinoma (PDAC) failure pattern. We investigated in a subset of locally advanced patients submitted to radiofrequency ablation (RFA) whether the assessment of SMAD4 status is a useful way to select the patients…
Methods- Clinical, radiological, and follow-up details of patients submitted to RFA for locally advanced pancreatic cancer (LAPC), in whom cytohistological material was available at our institution, were retrospectively retrieved. SMAD4 expression was evaluated by immunohistochemistry (IHC) and considered “negative” or “positive…
Results- The study population consisted of 30 patients. Thirteen patients (43.3%) received RFA upfront, whereas 17 (56.7%) after induction treatments. SMAD4 was mutant in 18 out of 30 patients (60%). The overall estimated post-RFA disease-specific survival (DSS) was 15 months (95% CI 11.64–18.35). The estimated post-RFA DSS of patients with wild-type and mutant SMAD4 was 22 and 12 months, respectively…
Conclusions- Within patients undergoing RFA for LAPC, SMAD4 analysis could segregate a subgroup of subjects with improved survival, who likely benefited from tumor ablation.